France· FR:63678345
KIMMTRAK 100 microgrammes/0,5 mL, solution à diluer pour perfusion
A tebentafusp product containing tébentafusp, registered in France by IMMUNOCORE IRELAND (IRLANDE). The same ATC class is registered in 11 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Tebentafusp is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XX75 (tebentafusp), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 7 of them publish a price we can compare per daily dose
Tebentafusp · ATC L01XX75
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tebentafusp costs, country by country.
Normalised to the WHO defined daily dose (9.7 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tebentafusp · price per daily dose (9.7 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1341.35
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TÉBENTAFUSP
- Manufacturer
- IMMUNOCORE IRELAND (IRLANDE)
- Country
- France (FR)
- ATC code
- L01XX75
- ATC class
- Tebentafusp
- Defined daily dose
- 9.7 mcg, P
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550891621 flacon(s) en verre de 0,5 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tebentafusp in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKIMMTRAKImmunocore Commercial LLC
- CanadaKIMMTRAKIMMUNOCORE IRELAND LIMITED
- SwitzerlandKimmtrak
- CzechiaKIMMTRAKImmunocore Ireland Limited, Dublin
- SpainKIMMTRAK 100 MICROGRAMOS/0,5 ML CONCENTRADO PARA SOLUCION PARA PERFUSIONImmunocore Ireland Limited
- FinlandKIMMTRAKImmunocore Ireland Limited
- United KingdomKimmtrak 100micrograms/0.5ml concentrate for solution for infusion vialsImmunocore Ltd
- BelgiumKimmtrak 100 µg/0.5 mlImmunocore Ireland
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kimmtrak
- Liechtenstein · Kimmtrak
- Norway · Kimmtrak
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/06d00b36-e0d4-4fc4-a5e3-ca1c42a49110 GET /v1/drugs/06d00b36-e0d4-4fc4-a5e3-ca1c42a49110?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63678345",
"date_amm": "2022-04-01",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/22/1630",
"substance": "TÉBENTAFUSP",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about tebentafusp.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.